Smart Drug Delivery Systems Market (Product: Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-on Sensors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Smart Drug Delivery Systems Market (Product: Connected Inhalers, Connected Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-on Sensors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Smart Drug Delivery Systems Market – Scope of Report

TMR’s report on the global smart drug delivery systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global smart drug delivery systems market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global smart drug delivery systems market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the smart drug delivery systems market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global smart drug delivery systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global smart drug delivery systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global smart drug delivery systems market.

The report delves into the competitive landscape of the global smart drug delivery systems market. Key players operating in the global smart drug delivery systems market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global smart drug delivery systems market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market smart drug delivery systems.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Smart Drug Delivery Systems Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
5. Key Insights
5.1. Smart Insulin Pen - Brand Analysis
5.2. Insulin Pen Delivery Devices Available in the U.S.
5.3. Insights on Digitization of Diabetes: Opportunities & Challenges
5.4. Key Industry Events (Partnership, Merger & Acquisition, etc.)
5.5. COVID-19 Impact Analysis
6. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Connected Inhalers
6.3.2. Connected Autoinjectors
6.3.3. Connected Pen Injectors
6.3.4. Connected Wearable Injectors
6.3.5. Add-on Sensors
6.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031
7.3.1. Injectable
7.3.2. Inhalation
7.3.3. Oral
7.4. Market Attractiveness Analysis, by Drug Delivery Mode
8. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Therapeutic Area, 2017–2031
8.3.1. Metabolic Disorders
8.3.2. Neurological Disorders
8.3.3. Respiratory Disorders
8.3.4. Hormonal Disorders
8.3.5. Others
8.4. Market Attractiveness Analysis, by Therapeutic Area
9. Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Home Care
9.3.4. Ambulatory Care Settings
9.3.5. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Smart Drug Delivery Systems Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Connected Inhalers
11.2.2. Connected Autoinjectors
11.2.3. Connected Pen Injectors
11.2.4. Connected Wearable Injectors
11.2.5. Add-on Sensors
11.2.6. Others
11.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031
11.3.1. Injectable
11.3.2. Inhalation
11.3.3. Oral
11.4. Market Value Forecast, by Therapeutic Area, 2017–2031
11.4.1. Metabolic Disorders
11.4.2. Neurological Disorders
11.4.3. Respiratory Disorders
11.4.4. Hormonal Disorders
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Home Care
11.5.4. Ambulatory Care Settings
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Drug Delivery Mode
11.7.3. By Therapeutic Area
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Smart Drug Delivery Systems Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Connected Inhalers
12.2.2. Connected Autoinjectors
12.2.3. Connected Pen Injectors
12.2.4. Connected Wearable Injectors
12.2.5. Add-on Sensors
12.2.6. Others
12.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031
12.3.1. Injectable
12.3.2. Inhalation
12.3.3. Oral
12.4. Market Value Forecast, by Therapeutic Area, 2017–2031
12.4.1. Metabolic Disorders
12.4.2. Neurological Disorders
12.4.3. Respiratory Disorders
12.4.4. Hormonal Disorders
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Home Care
12.5.4. Ambulatory Care Settings
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Drug Delivery Mode
12.7.3. By Therapeutic Area
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Connected Inhalers
13.2.2. Connected Autoinjectors
13.2.3. Connected Pen Injectors
13.2.4. Connected Wearable Injectors
13.2.5. Add-on Sensors
13.2.6. Others
13.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031
13.3.1. Injectable
13.3.2. Inhalation
13.3.3. Oral
13.4. Market Value Forecast, by Therapeutic Area, 2017–2031
13.4.1. Metabolic Disorders
13.4.2. Neurological Disorders
13.4.3. Respiratory Disorders
13.4.4. Hormonal Disorders
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Home Care
13.5.4. Ambulatory Care Settings
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Drug Delivery Mode
13.7.3. By Therapeutic Area
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Smart Drug Delivery Systems Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Connected Inhalers
14.2.2. Connected Autoinjectors
14.2.3. Connected Pen Injectors
14.2.4. Connected Wearable Injectors
14.2.5. Add-on Sensors
14.2.6. Others
14.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031
14.3.1. Injectable
14.3.2. Inhalation
14.3.3. Oral
14.4. Market Value Forecast, by Therapeutic Area, 2017–2031
14.4.1. Metabolic Disorders
14.4.2. Neurological Disorders
14.4.3. Respiratory Disorders
14.4.4. Hormonal Disorders
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Home Care
14.5.4. Ambulatory Care Settings
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Drug Delivery Mode
14.7.3. By Therapeutic Area
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Connected Inhalers
15.2.2. Connected Autoinjectors
15.2.3. Connected Pen Injectors
15.2.4. Connected Wearable Injectors
15.2.5. Add-on Sensors
15.2.6. Others
15.3. Market Value Forecast, by Drug Delivery Mode, 2017–2031
15.3.1. Injectable
15.3.2. Inhalation
15.3.3. Oral
15.4. Market Value Forecast, by Therapeutic Area, 2017–2031
15.4.1. Metabolic Disorders
15.4.2. Neurological Disorders
15.4.3. Respiratory Disorders
15.4.4. Hormonal Disorders
15.4.5. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Home Care
15.5.4. Ambulatory Care Settings
15.5.5. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Drug Delivery Mode
15.7.3. By Therapeutic Area
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2021)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. Strategic Overview
16.3.1.5. SWOT Analysis
16.3.2. Adherium Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. Strategic Overview
16.3.2.5. SWOT Analysis
16.3.3. Amiko Digital Health Limited
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. Strategic Overview
16.3.3.5. SWOT Analysis
16.3.4. Becton, Dickinson and Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. Strategic Overview
16.3.4.5. SWOT Analysis
16.3.5. BIOCORP
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. Strategic Overview
16.3.5.5. SWOT Analysis
16.3.6. CeQur Corporation
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. Strategic Overview
16.3.6.5. SWOT Analysis
16.3.7. Cognita Labs
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. Strategic Overview
16.3.7.5. SWOT Analysis
16.3.8. E3D Elcam Drug Delivery Devices
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. Strategic Overview
16.3.8.5. SWOT Analysis
16.3.9. H&T Presspart Manufacturing Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. Strategic Overview
16.3.9.5. SWOT Analysis
16.3.10. HCmed Innovations Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. Strategic Overview
16.3.10.5. SWOT Analysis
16.3.11. Medtronic plc
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. Strategic Overview
16.3.11.5. SWOT Analysis
16.3.12. Novo Nordisk
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. Strategic Overview
16.3.12.5. SWOT Analysis
16.3.13. Phillips-Medisize
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. Strategic Overview
16.3.13.5. SWOT Analysis
16.3.14. Sonceboz
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. Strategic Overview
16.3.14.5. SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings